Table 1.
RCTs included in the systematic review
| Author/year/ country | Setting | N AZM/standard care | Outcome | Outcome n AZM/comparison | Effect |
|---|---|---|---|---|---|
| ATOMIC2/ 2021/UK | Comm | 147/148 | Death or need for admission | 15/17 | OR: 0.91 (0.43–1.92), P = 0.80 |
| Time to admission | HR: 0.95 (0.46–1.96), P = 0.89 | ||||
| Maximum clinical severity | OR: 0.91 (0.57–1.46), P = 0.69 | ||||
| COALITION II/ 2020/Brazil | Hosp | 214/183 | Higher category of clinical status score | OR: 1.36 (0.94–1.97) | |
| Death | 90/73 | HR: 1.08 (0.79–1.47), P = 0.63 | |||
| Difference median length of admission (days) | 26/18 | 8.00 (0.81–15.19), P = 0.064 | |||
| Serious adverse events | 102/75 | No difference in adverse events P = 0.35 | |||
| QT prolongation | 47/42 | No difference. No difference in ventricular arrythmia or need for resuscitation | |||
| PRINCIPLE/ 2021/UK | Comm | 540/875 | Clinical recovery Day 28 | 402/631 | |
| Time to clinical recovery | HR: 1.08 (0.95–1.23) | ||||
| Need of admission | 16/28 | OR: 0.3 (–1.7 to 2.2) | |||
| RECOVERY/ 2021/UK | Hosp | 2582/5181 | Death | 561/1162 | RR: 0.97 (0.87–1.107), P = 0.50. This result was also not significant in different age or gender categories |
| Median length of admission (days) | 10/11 | ||||
| Discharged alive on Day 28 (%) | 68/69 | RR: 1.04 (0.98–1.10), P = 0.19 | |||
| Need for mechanical ventilation or death (%) | 25/26 | RR: 0.95 (0.87–1.03), P = 0.24 | |||
| Serious adverse events | 1/0 | No difference in arrythmias | |||
| Sekhavati/ Iran/2020 | Hosp | 56/55 | Mean length of admission (days) | 4.61/5.96 | P = 0.02 |
| Need for ICU | 2/7 | P = 0.070 | |||
| Death | 0/1 | P = 0.495 | |||
| No difference in QT prolongation or arrythmia |
AZM, azithromycin; Hosp, hospital; Comm, community.